Allergy influences the inflammatory status of the brain and enhances tau-phosphorylation

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2401-2412

  Sarlus, Heela ^a   Höglund, Caroline Olgart ^a,b   Karshikoff, Bianka ^a,b   Wang, Xiuzhe ^a   Lekander, Mats ^a,c   Schultzberg, Marianne ^a   Oprica, Mircea ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Immunoglobulin; Neuroinflammation; Tau phosphorylation

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; OVALBUMIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; BRAIN; CHEMISTRY; CHRONIC DISEASE; DISEASE MODEL; EOSINOPHILIA; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; LUNG LAVAGE; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION;

ALLERGENS; ALZHEIMER DISEASE; ANIMALS; BRAIN; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EOSINOPHILIA; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN; PHOSPHORYLATION; TAU PROTEINS;

ANIMALIA; MUS;

EID: 84866750285     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01556.x     Document Type: Article

References (58)

1. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009; 73: 768-74.
2. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004; 61: 668-72.
3. Dziedzic T. Systemic inflammatory markers and risk of dementia. Am J Alzheimers Dis Other Demen. 2006; 21: 258-62.
4. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995; 45: 51-5.
5. Cakala M, Malik AR, Strosznajder JB. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol Rep. 2007; 59: 164-72.
6. McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009; 34: 163-77.
7. Sanchez-Ramos J, Song S, Sava V, et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience. 2009; 163: 55-72.
8. Tsai KJ, Tsai YC, Shen CK. G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med. 2007; 204: 1273-80.
9. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997; 20: 154-9.
10. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992; 42: 631-9.
11. Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993; 162: 179-82.
12. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003; 60: 729-36.
13. Polydoro M, Acker CM, Duff K, et al. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009; 29: 10741-9.
14. Hanger DP, Seereeram A, Noble W. Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. Expert Rev Neurother. 2009; 9: 1647-66.
15. Chung SH. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep. 2009; 42: 467-74.
16. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998; 8: 65-72.
17. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol. 1998; 33: 371-8.
18. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989; 86: 7611-5.
19. Apelt J, Schliebs R. β-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001; 894: 21-30.
20. Tehranian R, Hasanvan H, Iverfeldt K, et al. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci Lett. 2001; 301: 54-8.
21. Tarkowski E, Liljeroth AM, Nilsson A, et al. Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001; 12: 314-7.
22. Garlind A, Brauner A, Hojeberg B, et al. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res. 1999; 826: 112-6.
23. Eriksson UK, Gatz M, Dickman PW, et al. Asthma, eczema, rhinitis and the risk for dementia. Dement Geriatr Cogn Disord. 2008; 25: 148-56.
24. Basso AS, Costa-Pinto FA, Britto LR, et al. Neural pathways involved in food allergy signaling in the mouse brain: role of capsaicin-sensitive afferents. Brain Res. 2004; 1009: 181-8.
25. Basso AS, Pinto FA, Russo M, et al. Neural correlates of IgE-mediated food allergy. J Neuroimmunol. 2003; 140: 69-77.
26. Campbell A, Oldham M, Becaria A, et al. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology. 2005; 26: 133-40.
27. Tonelli LH, Katz M, Kovacsics CE, et al. Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. Brain Behav Immun. 2009; 23: 784-93.
28. McMillan SJ, Lloyd CM. Prolonged allergen challenge in mice leads to persistent airway remodelling. Clin Exp Allergy. 2004; 34: 497-507.
29. Nials AT, Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech. 2008; 1: 213-20.
30. Van Hove CL, Maes T, Cataldo DD, et al. Comparison of acute inflammatory and chronic structural asthma-like responses between C57BL/6 and BALB/c mice. Int Arch Allergy Immunol. 2009; 149: 195-207.
31. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol. 1999; 12: 1101-6.
32. Elovaara I, Hietaharju A. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology? Acta Neurol Scand. 2010; 122: 309-15.
33. Fabian RH, Ritchie TC. Intraneuronal IgG in the central nervous system. J Neurol Sci. 1986; 73: 257-67.
34. Hazama GI, Yasuhara O, Morita H, et al. Mouse brain IgG-like immunoreactivity: strain-specific occurrence in microglia and biochemical identification of IgG. J Comp Neurol. 2005; 492: 234-49.
35. Hulse RE, Swenson WG, Kunkler PE, et al. Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha. J Neurosci. 2008; 28: 12199-211.
36. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis. 2010; 37: 503-9.
37. Andoh T, Kuraishi Y. Expression of Fc epsilon receptor I on primary sensory neurons in mice. NeuroReport. 2004; 15: 2029-31.
38. Andoh T, Kuraishi Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. Faseb J. 2004; 18: 182-4.
39. van der Kleij H, Charles N, Karimi K, et al. Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors. J Allergy Clin Immunol. 2010; 125: 757-60.
40. D'Andrea MR. Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease. Brain Res. 2003; 982: 19-30.
41. D'Andrea MR. Evidence that immunoglobulin-positive neurons in Alzheimer's disease are dying via the classical antibody-dependent complement pathway. Am J Alzheimers Dis Other Demen. 2005; 20: 144-50.
42. Blennow K, Wallin A, Davidsson P, et al. Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1990; 4: 79-86.
43. Blennow K, Wallin A, Fredman P, et al. Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease. Eur Neuropsychopharmacol. 1990; 1: 79-81.
44. Ban E, Haour F, Lenstra R. Brain interleukin 1 gene expression induced by peripheral lipopolysaccharide administration. Cytokine. 1992; 4: 48-54.
45. Eriksson C, Nobel S, Winblad B, Schultzberg M. Expression of interleukin-1α and β, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides. Cytokine. 2000; 12: 423-31.
46. Teeling JL, Felton LM, Deacon RM, et al. Sub-pyrogenic systemic inflammation impacts on brain and behavior, independent of cytokines. Brain Behav Immun. 2007; 21: 836-50.
47. Bay-Richter C, Janelidze S, Hallberg L, Brundin L. Changes in behaviour and cytokine expression upon a peripheral immune challenge. Behav Brain Res. 2011; 222: 193-9.
48. Kitazawa M, Oddo S, Yamasaki TR, et al. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005; 25: 8843-53.
49. Lee DC, Rizer J, Selenica ML, et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation. 2010; 7: 56.
50. Goedert M, Jakes R, Crowther RA, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J. 1994; 301 (Pt 3): 871-7.
51. Kimura T, Ono T, Takamatsu J, et al. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia. 1996; 7: 177-81.
52. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis. 2007; 12: 365-75.
53. Zilka N, Stozicka Z, Kovac A, et al. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol. 2009; 209: 16-25.
54. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res. 2004; 295: 245-57.
55. Bhaskar K, Konerth M, Kokiko-Cochran ON, et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010; 68: 19-31.
56. DiCarlo G, Wilcock D, Henderson D, et al. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging. 2001; 22: 1007-12.
57. Herber DL, Mercer M, Roth LM, et al. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol. 2007; 2: 222-31.
58. Malm TM, Koistinaho M, Parepalo M, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis. 2005; 18: 134-42.